Marekani - Kiingereza - NLM (National Library of Medicine)

akorn - labetalol hydrochloride (unii: 1gev3baw9j) (labetalol - unii:r5h8897n95) - labetalol hydrochloride 5 mg in 1 ml - labetalol hcl injection is indicated for control of blood pressure in severe hypertension. labetalol hcl injection is contraindicated in bronchial asthma, overt cardiac failure, greater than first degree heart block, cardiogenic shock, severe bradycardia, other conditions associated with severe and prolonged hypotension, and in patients with a history of hypersensitivity to any component of the product (see warnings ). beta-blockers, even those with apparent cardioselectivity, should not be used in patients with a history of obstructive airway disease, including asthma.

Marekani - Kiingereza - NLM (National Library of Medicine)

west-ward pharmaceuticals corp - labetalol hydrochloride (unii: 1gev3baw9j) (labetalol - unii:r5h8897n95) - labetalol hydrochloride 5 mg in 1 ml - labetalol hcl injection, usp is indicated for control of blood pressure in severe hypertension. labetalol hcl injection is contraindicated in bronchial asthma, overt cardiac failure, greater-than-first-degree heart block, cardiogenic shock, severe bradycardia, other conditions associated with severe and prolonged hypotension, and in patients with a history of hypersensitivity to any component of the product (see warnings). beta-blockers, even those with apparent cardioselectivity, should not be used in patients with a history of obstructive airway disease, including asthma.

Marekani - Kiingereza - NLM (National Library of Medicine)

bryant ranch prepack - labetalol hydrochloride (unii: 1gev3baw9j) (labetalol - unii:r5h8897n95) - labetalol hydrochloride 200 mg - labetalol hydrochloride tablets, usp are indicated in the management of hypertension. labetalol hydrochloride tablets, usp may be used alone or in combination with other antihypertensive agents, especially thiazide and loop diuretics. labetalol hcl tablets are contraindicated in bronchial asthma, overt cardiac failure, greater-than-first-degree heart block, cardiogenic shock, severe bradycardia, other conditions associated with severe and prolonged hypotension, and in patients with a history of hypersensitivity to any component of the product (see warnings ). beta-blockers, even those with apparent cardioselectivity, should not be used in patients with a history of obstructive airway disease, including asthma.

Marekani - Kiingereza - NLM (National Library of Medicine)

a-s medication solutions - labetalol hydrochloride (unii: 1gev3baw9j) (labetalol - unii:r5h8897n95) - labetalol hydrochloride 100 mg - labetalol hydrochloride tablets, usp are indicated in the management of hypertension. labetalol hydrochloride tablets, usp may be used alone or in combination with other antihypertensive agents, especially thiazide and loop diuretics. labetalol hydrochloride tablets are contraindicated in bronchial asthma, overt cardiac failure, greater-than-first-degree heart block, cardiogenic shock, severe bradycardia, other conditions associated with severe and prolonged hypotension, and in patients with a history of hypersensitivity to any component of the product (see warnings ). beta-blockers, even those with apparent cardioselectivity, should not be used in patients with a history of obstructive airway disease, including asthma.  

Marekani - Kiingereza - NLM (National Library of Medicine)

mylan institutional inc. - labetalol hydrochloride (unii: 1gev3baw9j) (labetalol - unii:r5h8897n95) - labetalol hydrochloride 100 mg - labetalol hydrochloride tablets usp are indicated in the management of hypertension. labetalol hydrochloride tablets usp may be used alone or in combination with other antihypertensive agents, especially thiazide and loop diuretics. labetalol hydrochloride is contraindicated in bronchial asthma, overt cardiac failure, greater-than-first-degree heart block, cardiogenic shock, severe bradycardia, other conditions associated with severe and prolonged hypotension, and in patients with a history of hypersensitivity to any component of the product (see warnings). beta-blockers, even those with apparent cardioselectivity, should not be used in patients with a history of obstructive airway disease, including asthma.

Marekani - Kiingereza - NLM (National Library of Medicine)

american health packaging - labetalol hydrochloride (unii: 1gev3baw9j) (labetalol - unii:r5h8897n95) - labetalol hydrochloride 100 mg - labetalol hydrochloride tablets, usp are indicated in the management of hypertension. labetalol hydrochloride tablets, usp may be used alone or in combination with other antihypertensive agents, especially thiazide and loop diuretics. labetalol hydrochloride is contraindicated in bronchial asthma, overt cardiac failure, greater-than-first-degree heart block, cardiogenic shock, severe bradycardia, other conditions associated with severe and prolonged hypotension, and in patients with a history of hypersensitivity to any component of the product [see warnings ] . beta-blockers, even those with apparent cardioselectivity, should not be used in patients with a history of obstructive airway disease, including asthma.

Marekani - Kiingereza - NLM (National Library of Medicine)

a-s medication solutions - labetalol hydrochloride (unii: 1gev3baw9j) (labetalol - unii:r5h8897n95) - labetalol hydrochloride tablets are indicated in the management of hypertension. labetalol hydrochloride tablets may be used alone or in combination with other antihypertensive agents, especially thiazide and loop diuretics. labetalol hydrochloride tablets are contraindicated in bronchial asthma, overt cardiac failure, greater-than-first-degree heart block, cardiogenic shock, severe bradycardia, other conditions associated with severe and prolonged hypotension, and in patients with a history of hypersensitivity to any component of the product (see warnings). beta-blockers, even those with apparent cardioselectivity, should not be used in patients with a history of obstructive airway disease, including asthma.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

southern xp ip pty ltd - labetalol hydrochloride, quantity: 50 mg - injection, solution - excipient ingredients: hydrochloric acid; sodium hydroxide; water for injections - the emergency treatment of severe hypertension when prompt and urgent reduction of blood pressure is essential

Marekani - Kiingereza - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - labetalol hydrochloride (unii: 1gev3baw9j) (labetalol - unii:r5h8897n95) - labetalol hcl injection is indicated in severe hypertension, to lower blood pressure. labetalol hydrochloride injection iscontraindicated in patients with: - bronchial asthma or obstructive airway disease. - severe sinus bradycardia: - heart block greater than first degree. - cardiogenic shock. - iv administration of non-dihydropyridine calcium-channel antagonists (e.g., verapamil) - hypersensitivity reactions, including anaphylaxis, to labetalol risk summary the extensive experience with use of labetalol in pregnant women, based on published interventional and observational studies, has not identified a drug-associated risk for major birth defects, miscarriage, or adverse maternal or fetal outcomes (see data). untreated hypertension during pregnancy can lead to serious adverse outcomes for the mother and the fetus (see clinical considerations) . in animal reproduction studies, oral administration of labetalol to pregnant rats and rabbits during organogenesis at doses up to approximately six and four times the maximum recommended human dose (mrhd), respectively, resulted in no fetal malformations; however, increased fetal resorptions were seen in both species at doses approximating the mrhd (see data) . in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. the background risk of major birth defects and miscarriage for the indicated population is unknown. clinical considerations disease-associated maternal and/or embryo/fetal risk hypertension in pregnancy increases the maternal risk for pre-eclampsia, gestational diabetes, premature delivery, and delivery complications (e.g., need for cesarean section, and post-partum hemorrhage). hypertension increases the fetal risk for intrauterine growth restriction and intrauterine death.  pregnant women with hypertension should be carefully monitored and managed accordingly. fetal/neonatal adverse reactions labetalol crosses the placenta. neonates born to mothers who are receiving labetalol during pregnancy, may be at risk for hypotension, bradycardia, hypoglycemia, and respiratory depression. neonates should be monitored for symptoms of hypotension, bradycardia, hypoglycemia and respiratory depression and manage accordingly. data human data data from published interventional and observational studies did not demonstrate an association between major congenital malformations and the use of labetalol in pregnancy, however, most studies reported the maternal use of intravenous labetalol occurring after 20 weeks gestation.the published literature has reported inconsistent findings of intrauterine growth retardation, preterm birth and perinatal mortality with maternal use of labetalol during pregnancy; however, these studies have methodological limitations hindering interpretation. these studies cannot definitively establish the absence of risk during pregnancy. animal data teratogenic studies were performed with labetalol in rats and rabbits at oral doses up to approximately six and four times the maximum recommended human dose (mrhd), respectively. no reproducible evidence of fetal malformations was observed. increased fetal resorptions were seen in both species at doses approximating the mrhd. a teratology study performed with labetalol in rabbits at intravenous doses up to 1.7 times the mrhd revealed no evidence of drug-related harm to the fetus. oral administration of labetalol to rats during late gestation through weaning at doses of two to four times the mrhd caused a decrease in neonatal survival. risk summary available published data report the presence oflabetalol in human milk at low levels. there are no data on the effects on the breastfed infant and on milk production. the developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for labetalol and any potential adverse effects on the breastfed infant from labetalol or from the underlying maternal condition. infertility based on the published literature, beta blockers, including labetalol, may cause erectile dysfunction and inhibit sperm motility. safety and effectiveness in pediatric patients have not been established. some pharmacokinetic studies indicate that the elimination of labetalol is reduced in elderly patients [see clinical pharmacology (12.3)] . geriatric patients treated with labetalol could initiate therapy at the currently recommended dose of 2 mg/minute by continuous intravenous infusion; however, lower maintenance dosages are generally required for elderly patients than nonelderly patients. monitor blood pressure and adjust the dosage and duration of infusion accordingly until the desired response is obtained [see dosage and administration (2 ) ] .

Marekani - Kiingereza - NLM (National Library of Medicine)

st. mary's medical park pharmacy - labetalol hydrochloride (unii: 1gev3baw9j) (labetalol - unii:r5h8897n95) - labetalol hydrochloride tablets are indicated in the management of hypertension. labetalol hydrochloride tablets may be used alone or in combination with other antihypertensive agents, especially thiazide and loop diuretics. labetalol hydrochloride tablets are contraindicated in bronchial asthma, overt cardiac failure, greater-than-first-degree heart block, cardiogenic shock, severe bradycardia, other conditions associated with severe and prolonged hypotension, and in patients with a history of hypersensitivity to any component of the product (see warnings). beta-blockers, even those with apparent cardioselectivity, should not be used in patients with a history of obstructive airway disease, including asthma.